One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Facts and Myths About Stage Migration: Should the Will Rogers Phenomenon Ride off into the Distance?
Stefano Fanti a,b Elisabetta Lalumera c,* Rodney Hicks
doi : 10.1016/j.euo.2021.12.005
Volume 6, Issue 1, February 2023, Pages 1-3
Long-term Health-related Quality of Life in Patients on Active Surveillance for Prostate Cancer: A Systematic Review
Daryl Thompson a , Jonathan G. Bensley b , Jake Tempo a , Behfar Ehdaie c , Sigrid Carlsson c , James Eastham c , Damien Bolton a , Marlon Perera a,c , Nathan Papa
doi : 10.1016/j.euo.2022.09.001
Volume 6, Issue 1, February 2023, Pages 4-15
Active surveillance (AS) represents the preferred treatment option in patients with low-risk prostate cancer. Optimised patient selection has enabled more patients to be managed with AS for a longer time. Thus, there is growing interest in its effect on long-term quality of life compared with interventional management.
Role of Local and/or Metastasis-directed Therapy in Patients with Hormone-sensitive M1a Prostate Cancer—A Systematic Review
Hilda A. de Barros a,b,*, Isabeau van Beurden a,b , Matteo Droghetti a,b,c , Erica A. Wilthagen d , Oktay O ̈zman a,b , Andries M. Bergman e , Shafak Aluwini f , R. Jeroen A. van Moorselaar b,g , Maarten L. Donswijk h , Pim J. van Leeuwen a,b , Henk G. van der Poel
doi : 10.1016/j.euo.2022.10.002
Volume 6, Issue 1, February 2023, Pages 16-27
It remains unclear whether men with hormone-sensitive prostate cancer (PCa) metastasized to nonregional lymph nodes (M1a) benefit from prostate-directed therapy (PDT) and/or metastasis-directed therapy (MDT).
Review of Prospective Trials Assessing the Role of Stereotactic Body Radiation Therapy for Metastasis-directed Treatment in Oligometastatic Genitourinary Cancers
Mai Anh Huynh a,*, Chad Tang b , Shankar Siva c , Alejandro Berlin d , Raquibul Hannan e , Andrew Warner f , Bridget Koontz g , Gert De Meeleer h , David Palma f , Piet Ost i , Phuoc T. Tran
doi : 10.1016/j.euo.2022.09.007
Volume 6, Issue 1, February 2023, Pages 28-38
Emerging evidence supports the use of stereotactic body radiation therapy (SBRT) as metastatic-directed therapy (MDT) for oligometastatic genitourinary cancers; however, the prospective data to guide its application as an alternative standard of care remain limited.
Stereotactic Body Radiotherapy for Oligometastatic and Oligoprogressive Genitourinary Malignancies: A Work in Progress
Patrick J. Horsley a , Andrew Kneebone
doi : 10.1016/j.euo.2022.11.002
Volume 6, Issue 1, February 2023, Pages 39-40
Multicenter External Validation of a Nomogram for Predicting Positive Prostate-specific Membrane Antigen/Positron Emission Tomography Scan in Patients with Prostate Cancer Recurrence
Lorenzo Bianchi a,b , Paolo Castellucci c , Andrea Farolfi c,*, Matteo Droghetti a , Carlos Artigas d , Jose Leite e , Paola Corona f , Qaid Ahmed Shagera d , Renata Moreira e , Christian Gonza �lez f , Marcelo Queiroz g , Felipe de Galiza Barbosa g , Riccardo Schiavina a,b , Desiree Deandreis h , Stefano Fanti c , Francesco Ceci
doi : 10.1016/j.euo.2021.12.002
Volume 6, Issue 1, February 2023, Pages 41-48
A nomogram has recently been developed to predict 68
Detection of Clinically Significant Prostate Cancer Using Targeted Biopsy with Four Cores Versus Target Saturation Biopsy with Nine Cores in Transperineal Prostate Fusion Biopsy: A Prospective Randomized Trial
Yasemin Melisa Saner a , Manuel Wiesenfarth b , Vivienn Weru b , Boris Ladyzhensky c , Stephan Tschirdewahn a , Lukas Pu ̈llen a , David Bonekamp d , Henning Reis e , Ulrich Krafft a , Jochen HeÞ a , Claudia Kesch a , Christopher Darr a , Michael Forsting f , Axel Wetter f , Lale Umutlu f , Johannes Haubold f , Boris Hadaschik a , Jan Philipp Radtke
doi : 10.1016/j.euo.2022.08.005
Volume 6, Issue 1, February 2023, Pages 49-55
Multiparametric magnetic resonance imaging (mpMRI) and targeted biopsy (TB) facilitate accurate detection of clinically significant prostate cancer (csPC). However, it remains unclear how targeted cores should be applied for accurate diagnosis of csPC.
The Optimal Prostate Biopsy in the Era of Multiparametric Magnetic Resonance Imaging
Michael Smigelski, Samir S. Taneja
doi : 10.1016/j.euo.2022.10.006
Volume 6, Issue 1, February 2023, Pages 56-57
Hyperthermic Mitomycin C in Intermediate-risk Non–muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial
Javier C. Angulo a,b,*, Jose � L. A �lvarez-Ossorio c , Jose � L. Domı �nguez-Escrig d , Jose � L. Moyano e , Alejandro Sousa f , Jesu �s M. Ferna �ndez g , Francisco Go �mez-Veiga h , Miguel Unda i , Joaquı �n Carballido j , Victor Carrero k , Toma �s Fernandez-Aparicio l , A �ngel Garcı �a de Jalo �n m , Eduardo Solsona d , Brant Inman n , Joan Palou
doi : 10.1016/j.euo.2022.10.008
Volume 6, Issue 1, February 2023, Pages 58-66
Optimising therapeutic strategies of intermediate-risk non–muscle-invasive bladder cancer (IR-NMIBC) is needed.
Highly Sensitive and Specific Detection of Bladder Cancer via Targeted Ultra-deep Sequencing of Urinary DNA
Douglas G. Ward a , Laura Baxter b , Sascha Ott b,c , Naheema S. Gordon a , Junhui Wang d , Prashant Patel a,d , Kim Piechocki e , Lee Silcock e , Chris Sale e , Maurice P. Zeegers f , K.K. Cheng g , Nicholas D. James h , Richard T. Bryan a,*, BladderPath Trial Management Group
doi : 10.1016/j.euo.2022.03.005
Volume 6, Issue 1, February 2023, Pages 67-75
There is an unmet need for an accurate, validated, noninvasive test for diagnosing and monitoring bladder cancer (BC). Detection of BC-associated mutations in urinary DNA via targeted deep sequencing could meet this need.
International Multi-institutional Characterization of the Perioperative Morbidity of Metastasectomy for Renal Cell Carcinoma
Timothy D. Lyon a,b,y, Eduard Roussel c,y, Vidit Sharma d , Gianpiero Carames e , Christine M. Lohse f , Brian A. Costello g , Stephen A. Boorjian d , R.Houston Thompson d , Steven Joniau c , Maarten Albersen c , Bradley C. Leibovich
doi : 10.1016/j.euo.2022.11.003
Volume 6, Issue 1, February 2023, Pages 76-83
Surgical resection of metastatic renal cell carcinoma (mRCC) has been associated with better cancer-specific survival; however, high-quality data on its perioperative morbidity are lacking.
Comprehensive Management of Renal Masses in Solitary Kidneys
Yosuke Yasuda a,b,y, JJ.H. Zhang a,c,y, Worapat Attawettayanon a,d,y, Nityam Rathi a , Lamont Wilkins a,e , Gustavo Roversi a , Ao Zhang a , Joao Pedro Emrich Accioly a , Snehi Shah a , Carlos Munoz-Lopez a , Diego Aguilar Palacios a , Martin Hofmann a , Rebecca A. Campbell a , Jihad Kaouk a , Georges-Pascal Haber a , Mohamad Eltemamy a , Venkatesh Krishnamurthi a , Robert Abouassaly a , Charles Martin III f , Jianbo Li a,g , Christopher Weight a , Steven C. Campbell a,
doi : 10.1016/j.euo.2022.11.004
Volume 6, Issue 1, February 2023, Pages 84-94
A renal mass in a solitary kidney (RMSK) has traditionally been managed with partial nephrectomy (PN), although radical nephrectomy (RN) is occasionally required. Most RMSK studies have focused on patients for whom PN was achieved.
Prostate-specific Membrane Antigen–radioguided Surgery Facilitates Pelvic Lymph Node Dissection During Radical Prostatectomy for the Treatment of Locally Advanced Prostate Cancer with Regional Lymph Node Metastases
Lukas Lunger a,y, Lisa Steinhelfer b,y, Philipp Korn a,y, Matthias Eiber b , Tobias Maurer a,à , Jakob Bu ̈chler a , Thomas Horn a , Ju ̈rgen E. Gschwend a , Matthias M. Heck
doi : 10.1016/j.euo.2022.12.001
Volume 6, Issue 1, February 2023, Pages 95-98
Lymph node metastases (LNMs) are common in intermediate- to high-risk prostate cancer (PC) and may be missed during extended pelvic lymph node dissection (ePLND). Here we report on the use of prostate-specific membrane antigen (PSMA)-radioguided surgery (RGS) during open radical prostatectomy (RP) with ePLND to resect locoregional LNMs identified on preoperative PSMA positron emission tomography (PET).
Diagnostic Value of the Vesical Imaging-Reporting and Data System in Bladder Urothelial Carcinoma with Variant Histology
Yuki Arita a,*, Soichiro Yoshida b , Keisuke Shigeta c , Thomas C. Kwee d , Hiromi Edo e , Naoko Okawara a , Masahiro Hashimoto a , Ryota Ishii f , Ryo Ueda g , Shuji Mikami h , Motohiro Fujiwara b , Yuma Waseda b , Eiji Kikuchi i , Yasuhisa Fujii b , Masahiro Jinzaki
doi : 10.1016/j.euo.2022.07.006
Volume 6, Issue 1, February 2023, Pages 99-102
The value of the Vesicle Imaging-Reporting and Data System (VI-RADS) in the diagnosis of muscle-invasive bladder cancer (MIBC) for urothelial carcinoma with variant histology (VUC) remains unknown.
Intermediate-risk Prostate Cancer—A Sheep in Wolf’s Clothing?
Isabel Heidegger a, *, Freddie C. Hamdy b , Roderick C.N. van den Bergh c , Axel Heidenreich d,e , Michiel Sedelaar f , Morgan Roupret g , on behalf of the EAU Section of Oncological Urology Board (ESOU)
doi : 10.1016/j.euo.2021.07.004
Volume 6, Issue 1, February 2023, Pages 103-109
This case-based discussion describes a 65-year-old man newly diagnosed with International Society of Urological Pathology (ISUP) grade 2 prostate cancer (PCa). According to the European Association of Urology classification system, the patient harbors an intermediate-risk cancer.
p53 Immunohistochemistry to Identify Very High-risk Primary Prostate Cancer: A Prospective Cohort Study with Three Decades of Follow-up
Konrad H. Stopsack a,b,1 Daniela Correia Salles c,1,2 J. Bailey Vaselkiv a Sydney T. Grob a Lorelei A. Mucci a,3 Tamara L. Lotan
doi : 10.1016/j.euo.2021.12.003
Volume 6, Issue 1, February 2023, Pages 110-112
